Atopy and risk of non-Hodgkin lymphoma.
BACKGROUND
A possible connection between allergy and cancer has been suspected, but allergy-related conditions or atopy have been inconsistently associated with reduced risks of non-Hodgkin lymphoma. We investigated this association in a population-based case-control study and in a prospective study with prediagnostic blood specimens.


METHODS
We carried out a population-based study of 3055 case patients with non-Hodgkin lymphoma and 3187 control subjects in Denmark and Sweden, including questionnaire information on allergy and blood specimens, and a nested case-control study within a prospective cohort of more than 400,000 Finnish women. In the second study, serum specimens from the 198 case patients who developed non-Hodgkin lymphoma within a median of 8.9 years after the blood was drawn were matched with serum specimens from 594 control subjects. In both studies, laboratory-based evidence of allergy (atopy) was determined in serum on the basis of specific IgE reactivity to common inhalant allergens. Dissemination of disease was classified by the Ann Arbor system. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by logistic regression.


RESULTS
In the first study, ever having hay fever, but not other allergic conditions, was associated with a reduced risk of non-Hodgkin lymphoma. In particular, subjects with specific IgE reactivity in serum had a 32% (95% CI = 20% to 42%) lower risk of overall non-Hodgkin lymphoma than those without such reactivity. However, among case patients, dissemination of the disease was strongly inversely associated with specific IgE reactivity. In the second (i.e., prospective) study, no association was found between non-Hodgkin lymphoma and specific IgE reactivity, except possibly immediately before a diagnosis of non-Hodgkin lymphoma (> or = 10 years before diagnosis, OR = 1.00, 95% CI = 0.48 to 2.09; 5-9 years before, OR = 0.95, 95% CI = 0.50 to 1.84; 1-4 years before, OR = 0.33, 95% CI = 0.11 to 1.02; and < 1 year before, OR = 0.27, 95% CI = 0.03 to 2.31).


CONCLUSIONS
Allergy may not be causally associated with the risk of non-Hodgkin lymphoma. The inverse association observed in some case-control studies may arise because non-Hodgkin lymphoma suppresses the immunologic response to allergens.
Melbye
Mads
M
Department of Epidemiology Research, Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen, Denmark. mme@ssi.dk
Smedby
Karin Ekström
KE
Lehtinen
Tuula
T
Rostgaard
Klaus
K
Glimelius
Bengt
B
Munksgaard
Lars
L
Schöllkopf
Claudia
C
Sundström
Christer
C
Chang
Ellen T
ET
Koskela
Pentti
P
Adami
Hans-Olov
HO
Hjalgrim
Henrik
H
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000150:complications* / Q000453:epidemiology; D007073:Immunoglobulin E / Q000276:immunology; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011446:Prospective Studies; D012189:Retrospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000150:complications; D018570:Risk Assessment; D012307:Risk Factors; D015983:Selection Bias; D011795:Surveys and Questionnaires; D013548:Sweden / Q000453:epidemiology
D007073:Immunoglobulin E